SphingoTec announces results from the first #prospective study demonstrating Proenkephalin A 119-159 (#penKid) as a discriminatory biomarker for successful liberation from CRRT in #cardiac #surgery patients with acute kidney injury (AKI). Read more sphingotec.com/news/detail/as…

As the life sciences community converges in Milan, we're excited to connect with innovators and leaders at BIO-Europe Spring 2025. Our focus is out-licensing our innovative biomarkers to address critical conditions such as #AKI and #sepsis. Join us in Milan #BioEuropeSpring

We're excited to join forces with Boditech Med at the #ISICEM25 in Brussels! Our experts, Florian Uhle and Michal Bagrowski, will be supporting our license partner Boditech at booth #2.23, where they will showcase the AFIAS sphingotest® penKid® assay.

SphingoTec announces the publication of real-world data on the effectiveness of penKid in improving kidney function assessment in ICUs. Read here the full press release ow.ly/f3Wv50VAFgO

It’s a wrap from #EuroMedLab Brussels! Great discussions with industry leaders on bringing diagnostic innovation to critical care. Thanks to all who shared insights—collaboration drives better patient outcomes. Excited to build on these connections!

SphingoTec is at #ERA2025 in Vienna with Dr. Florian Uhle. PenKid features in the central AKI session, highlighting the role of functional biomarkers in critical care for early AKI detection. Proud to support advances in kidney health. #AKI #penKid

Honored to join the 43rd Vicenza Course on AKI & Critical Care Nephrology! Sphingotec’s penkid took center stage—grateful for the dialogue & expert insights on advancing AKI diagnostics with Prof. Lui Forni & the community. #CriticalCare #Nephrology #VicenzaCourse2025

In a landmark study published in Transplant International, Proenkephalin A 119-159 (penKid) is identified as a reliable biomarker for the early and precise assessment of graft function trajectories following kidney transplantation. ow.ly/b41V50WilsM

In the heart of Chicago, SphingoTec is connecting with peers at ADLM 2025. Our Managing Directors, Deborah Bergmann and Florian Uhle, are engaging with industry leaders to explore opportunities that advance our commitment to improving critical care diagnostics.

Proenkephalin A 119-159 (penKid): A Promising Biomarker for Early AKI Detection. The review places penKid as a valuable addition to the current AKI diagnostic toolbox for earlier diagnosis, enabling timely interventions for better long-term outcomes. doi.org/10.1007/s00134…

🌟 New S3 Sepsis Guidelines stress timely, flexible KRT for sepsis patients, but give no advice on stopping KRT. This clinical gap highlights the need for better kidney monitoring tools—innovations like penKid may help. register.awmf.org/de/leitlinien/… #SepsisCare #S3Guidelines #AKI

Dr. Frian Uhle, CMO and managing director at SphingoTec, attended the official launch of the ADORABLE consortium. Together, the ADORABLE consortium and innovative biomarkers like penKid aim to transform donor organ evaluation and post-transplant care. adorable-consortium.org

We are heading to MEDICA - Leading International Trade Fair this week!🫱🏼‍🫲🏼If you’re attending, let’s connect and join Deborah Bergmann at #MEDICA2025 to explore SphingoTec’s innovative diagnostic solutions for critical care.

Thrilled: penKid at DIVI25! Dr Birte Arlt presents meta-analysis from prospective studies (>2,200 sepsis pts): Spots kidney risks even w/ normal creatinine—key for early action. Session: Sepsis/Infektiologie 2, 04.12. 12:30-14:00, E-Poster Halle H. #penKid #Sepsis #DIVI25 #ICU

Proenkephalin A 119–159 (#penKid) took center stage at #DIVI25 in Beendigung des Nierenersatzes: Praxis und Evidenz (“Discontinuation of Renal Replacement Therapy”). Learn more in our whitepaper: sphingotec.eu/resources

New penKid data in CKD: Study w/ 4,700+ patients from 3 cohorts (~8.7yr follow-up) shows strong inverse link to renal function & predicts adverse outcomes—adding value beyond AKI. Enables risk stratification & better monitoring. academic.oup.com/ndt/advance-ar…

🚀 SphingoTec is excited to join BIO-Europe this year. Representing SphingoTec: Deborah Bergmann, CEO & Managing Partner and Nicole Witzmann, CFO. Write us to schedule 1:1 meetings. 📅 March 23-25, 2026 | Feira Internacional de Lisboa

New meta-analysis: #penKid predicts worsening renal function (WRF) and 28‑day mortality in sepsis—even when serum creatinine is normal. From >2,200 patients, penKid adds value beyond creatinine for early risk assessment. link.springer.com/article/10.118…

Proud to join the conversation on kidney care and clinical trial innovation at the KDCT 2026 Workshop. Dr. Florian Uhle represented SphingoTec in Session 9A on AI innovations in AKI trial design, while Deborah Bergmann connected with industry leaders to advance kidney diagnostics

SphingoTec GmbH announces the launch of the ELISA sphingotest® penKid®, a new assay designed to make testing of its proprietary biomarker broadly accessible to research laboratories and pharmaceutical partners. sphingotec.eu/sphingotec-int…